High throughput screening for SARS-CoV-2 inhibitors targeting 5 helix bundle
SLAS Discovery · 2025
DOI: 10.1016/j.slasd.2025.100262 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLAS Discovery, 2025. Verfasst von Emery Smith und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, High-throughput Screening Center, Department of Molecular Medicin…. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, SARS-CoV-2, Antiviral Agents, Spike Glycoprotein, Coronavirus. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Department of Molecular Medicine, University of Pavia.
Abstract (Originalsprache)
SARS-CoV-2 and other related viruses enter host cells via receptor recognition and membrane fusion. A crucial part of this is mediated by 5HB which is capable of binding to the viral spike heptad repeats (HR2) making 5HB a potential druggable target of virus entry. Thus, we constructed a 5-Helix Bundle (5HB) pentamer assay for the purpose of identifying potential inhibitors SARS-CoV-2 virus entry. Following implementation and optimization into a 1536 well format, we validated this assay via a pilot HTS and proved we were able to find small molecule inhibitors that appear to compete with the 5HB binding to HR2. This allowed us to push forward and complete the full HTS campaign testing 635,262 compounds. Upon completion of the 5HB pentamer HTS, we also tested and validated a monomer version of the 5HB assay against a pilot screen and then used it to help confirm on-target activity. This allowed for the selection of 130 compounds which were tested in dose titration format against the 5HB pentamer assay. The same compounds were tested in secondary cell-based assays for SARS2 and Machupo virus entry via a dual luciferase transient transfection system. We also incorporated a live/dead cytotoxicity counterscreen. At the conclusion of these screens, 41 compounds were found to be selective inhibitors of the 5HB pentamer assay. From these assays, 31 compounds and analogs were selected which were tested in both the pentamer and monomer assays. 5 compounds emerged which showed good potency in both assays which were then tested in the SARS pseudo virus assay to round out this exercise.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, High-throughput Screening Center, Department of Molecular Medicine, Jupiter, FL 33458, USA.
- University of Minnesota, Department of Pharmacology, Minneapolis, MN 55455, USA.
- The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, High-throughput Screening Center, Department of Molecular Medicine, Jupiter, FL 33458, USA. Electronic address: spicert@ufl.edu.
Förderung
- NIH HHS
- NIAID NIH HHS
- Department of Molecular Medicine, University of Pavia
- National Institutes of Health National Institute of Allergy and Infectious Diseases
Zitieren
APA
Smith, E., Geng, Q., Shumate, J., Otsuka, Y., Scampavia, L., Bannister, T. D., & Spicer, T. P. (2025). High throughput screening for SARS-CoV-2 inhibitors targeting 5 helix bundle. SLAS Discovery. https://doi.org/10.1016/j.slasd.2025.100262
Vancouver
Smith E, Geng Q, Shumate J, Otsuka Y, Scampavia L, Bannister TD, et al. High throughput screening for SARS-CoV-2 inhibitors targeting 5 helix bundle. SLAS Discovery. 2025. doi:10.1016/j.slasd.2025.100262
BibTeX
@article{Smith2025,
author = {Smith, Emery and Geng, Qibin and Shumate, Justin and Otsuka, Yuka and Scampavia, Louis and Bannister, Thomas D and Spicer, Timothy P},
title = {High throughput screening for SARS-CoV-2 inhibitors targeting 5 helix bundle},
journal = {SLAS Discovery},
year = {2025},
doi = {10.1016/j.slasd.2025.100262}
}
EUVIMED